149 related articles for article (PubMed ID: 21294362)
1. [Evaluating the effectiveness of drugs. "The full potential of a therapy is often only clear after a number of years" (interview by Helmut Laschet)].
Pfundner H
MMW Fortschr Med; 2010 Dec; 152(51-52):10. PubMed ID: 21294362
[No Abstract] [Full Text] [Related]
2. [Consequences of the German AMNOG for the identification of study objectives to demonstrate clinical efficacy and cost effectiveness of innovative drugs].
Götte D
Dtsch Med Wochenschr; 2012 Feb; 137(6):274-80. PubMed ID: 22270904
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
Amir E; Seruga B; Martinez-Lopez J; Kwong R; Pandiella A; Tannock IF; Ocaña A
J Clin Oncol; 2011 Jun; 29(18):2543-9. PubMed ID: 21606435
[TBL] [Abstract][Full Text] [Related]
4. Japanese universal health care faces a crisis in cancer treatment.
Fujiwara Y; Yonemori K; Shibata T; Okita N; Ushirozawa N
Lancet Oncol; 2015 Mar; 16(3):251-2. PubMed ID: 25752548
[No Abstract] [Full Text] [Related]
5. [Unfairly implicated as cost drivers. New drugs without a chance?].
MMW Fortschr Med; 2004 Mar; 146(10):45. PubMed ID: 15347085
[No Abstract] [Full Text] [Related]
6. [The costs of new drugs compared to current standard treatment].
Ujeyl M; Schlegel C; Gundert-Remy U
Z Evid Fortbild Qual Gesundhwes; 2013; 107(7):461-7. PubMed ID: 24238023
[TBL] [Abstract][Full Text] [Related]
7. [New drugs must henceforth be better than the current standard. What remains for physician therapy autonomy?].
Schmidt K
MMW Fortschr Med; 2006 Dec; 148(49-50):61, 63. PubMed ID: 17619334
[No Abstract] [Full Text] [Related]
8. Multiple Dimensions of Value: Evaluative Frameworks for New Cancer Therapies.
Cheung MC; Sabharwal M; Chambers A; Han D; Sabarre KA; Chan K
J Clin Oncol; 2016 Apr; 34(12):1428-9. PubMed ID: 26884567
[No Abstract] [Full Text] [Related]
9. [New drugs in Spain -- when are they to be considered cost-effective alternatives and profitable investments for the National Health System? ].
Soto Alvarez J
Farm Hosp; 2004; 28(4):299-304. PubMed ID: 15369442
[No Abstract] [Full Text] [Related]
10. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
[TBL] [Abstract][Full Text] [Related]
11. [Cost-effectiveness evaluation of drugs: multidisciplinary collaboration and transparency are key].
Mueller EA; Kirch W
Med Klin (Munich); 2008 Oct; 103(10):712-6. PubMed ID: 18936896
[TBL] [Abstract][Full Text] [Related]
12. [AMNOG: Importance of the identification of target parameters for evidence of clinical effectiveness of innovative drugs].
Meyer F
Dtsch Med Wochenschr; 2012 Jun; 137(23):1268; author reply 1268. PubMed ID: 22644496
[No Abstract] [Full Text] [Related]
13. [Assessment of novel antidiabetic drugs in Germany. Do innovations still have a chance?].
Gallwitz B
MMW Fortschr Med; 2014 Jul; 156(13):57-60. PubMed ID: 25318228
[No Abstract] [Full Text] [Related]
14. [Prerequisites in prescribing practice: physician decision processes].
Dierks C
Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):620-4. PubMed ID: 9527454
[TBL] [Abstract][Full Text] [Related]
15. [Clinical studies in oncology--a challenge for clinical and academic pathology].
Röcken C
Dtsch Med Wochenschr; 2013 May; 138(20):1073-6. PubMed ID: 23670265
[No Abstract] [Full Text] [Related]
16. Drugs are scarce as mix of programs aims to ease access.
Brower V
J Natl Cancer Inst; 2009 Oct; 101(19):1304-6. PubMed ID: 19755680
[No Abstract] [Full Text] [Related]
17. [Cost of medications in the oncology sector in the context of health economics].
Walter E; Batista A
Wien Med Wochenschr; 2008; 158(7-8):227-33. PubMed ID: 18500477
[TBL] [Abstract][Full Text] [Related]
18. [The costs of depression and the cost-effectiveness of treatment].
König HH; Luppa M; Riedel-Heller S
Psychiatr Prax; 2010 Jul; 37(5):213-5. PubMed ID: 20597034
[No Abstract] [Full Text] [Related]
19. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval.
Sobrero A; Bruzzi P
J Clin Oncol; 2009 Dec; 27(35):5868-73. PubMed ID: 19826122
[No Abstract] [Full Text] [Related]
20. [KBV faulted: there is not enough money for drugs. They have caused the deficit for physicians!].
MMW Fortschr Med; 2004 Aug; 146(33-34):46-7. PubMed ID: 15526627
[No Abstract] [Full Text] [Related]
[Next] [New Search]
